ImmunoCellular Therapeutics Ltd (NYSEMKT:IMUC) announced that the Board of Directors has appointed Anthony Gringeri, PhD, as Chief Executive Officer and a member of …
ImmunoCellular Therapeutics Ltd (NYSEMKT:IMUC) announced that at the Special Meeting of Stockholders held on November 14, 2016, ImmunoCellular’s stockholders voted to approve a …
ImmunoCellular Therapeutics Ltd (NYSEMKT:IMUC) announced financial results for the third quarter of 2016 and provided an update on its research and development activities. Andrew …
ImmunoCellular Therapeutics Ltd (NYSEMKT:IMUC) announced financial results for the second quarter of 2016. Andrew Gengos, ImmunoCellular Chief Executive Officer, commented: “We are pleased …
ImmunoCellular Therapeutics Ltd (NYSEMKT:IMUC) announced the pricing of an underwritten public offering of 47,000,000 shares of its common stock and base warrants to …
ImmunoCellular Therapeutics Ltd (NYSEMKT:IMUC) reported progress in its two lead cancer immunotherapy clinical programs: the phase 3 registrational trial of ICT-107 for newly …
ImmunoCellular Therapeutics Ltd (NYSEMKT:IMUC) announced that the first patient has been treated in the phase 3 registrational trial of ICT-107, the Company’s lead …
ImmunoCellular Therapeutics Ltd (NYSEMKT:IMUC) announced financial results for the first quarter of 2016. Andrew Gengos, ImmunoCellular Chief Executive Officer, commented: “We continue to …
ImmunoCellular Therapeutics Ltd (NYSEMKT:IMUC) announced it has entered into a sponsored research agreement with Eduardo Davila, PhD, Associate Professor of Microbiology and Immunology …
ImmunoCellular Therapeutics Ltd (NYSEMKT:IMUC) announced the establishment of an agreement with a major Canadian cancer cooperative group, The Canadian Brain Tumour Consortium (CBTC), for the …